• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.

作者信息

Markman Maurie

机构信息

Cancer Treatment Centers of America, Philadelphia, PA, USA,

出版信息

Curr Oncol Rep. 2013 Oct;15(5):433-5. doi: 10.1007/s11912-013-0338-0.

DOI:10.1007/s11912-013-0338-0
PMID:23933889
Abstract
摘要

相似文献

1
Ovarian cancer survival: steady improvement, despite rhetoric to the contrary.
Curr Oncol Rep. 2013 Oct;15(5):433-5. doi: 10.1007/s11912-013-0338-0.
2
Platinum alone for chemotherapy for ovarian cancer?
Lancet. 1998 Nov 14;352(9140):1567-8. doi: 10.1016/S0140-6736(05)61037-9.
3
Consolidation/maintenance chemotherapy for ovarian cancer.卵巢癌的巩固/维持化疗
Curr Oncol Rep. 2003 Nov;5(6):454-8. doi: 10.1007/s11912-003-0005-y.
4
Salvage therapy for recurrent epithelial ovarian cancer.复发性上皮性卵巢癌的挽救治疗
Hematol Oncol Clin North Am. 2003 Aug;17(4):977-88. doi: 10.1016/s0889-8588(03)00057-1.
5
Chemotherapy: Topotecan or treosulfan--that is the question.
Nat Rev Clin Oncol. 2009 Oct;6(10):559-60. doi: 10.1038/nrclinonc.2009.144.
6
Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer.晚期卵巢癌的新辅助化疗或初次手术
N Engl J Med. 2010 Dec 9;363(24):2371-2; author reply 2372. doi: 10.1056/NEJMc1011061.
7
Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy.
Semin Oncol. 1991 Jun;18(3):255-69.
8
Management of ovarian cancer. An impressive history of improvement in survival and quality of life.
Oncology (Williston Park). 2006 Apr;20(4):347-54; discussion 354, 357-8, 364 passim.
9
Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer.
N Engl J Med. 2010 Dec 9;363(24):2371; author reply 2372. doi: 10.1056/NEJMc1011061.
10
Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients.
Br J Cancer. 1999 Jan;79(2):373-4.

引用本文的文献

1
Caregiver Burden in End-Stage Ovarian Cancer.晚期卵巢癌患者照料者的负担
Clin J Oncol Nurs. 2016 Apr;20(2):169-73. doi: 10.1188/16.CJON.169-173.

本文引用的文献

1
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.采用腹腔内化疗治疗 III 期上皮性卵巢癌的预后因素：一项妇科肿瘤学组研究。
Gynecol Oncol. 2013 Jul;130(1):12-8. doi: 10.1016/j.ygyno.2013.04.001. Epub 2013 Apr 8.
2
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.OCEANS：一项在铂敏感复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌患者中进行的化疗联合或不联合贝伐珠单抗的随机、双盲、安慰剂对照 III 期试验。
J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.
3
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.奥拉帕利维持治疗铂敏感复发性卵巢癌。
N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27.
4
A phase 3 trial of bevacizumab in ovarian cancer.贝伐珠单抗治疗卵巢癌的 III 期临床试验。
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
5
Incorporation of bevacizumab in the primary treatment of ovarian cancer.贝伐珠单抗在卵巢癌初始治疗中的应用。
N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.
6
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.多柔比星脂质体与托泊替康联合治疗复发性卵巢癌。
J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1.
7
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.聚乙二醇脂质体阿霉素和卡铂与紫杉醇和卡铂治疗铂敏感复发性晚期卵巢癌患者的比较。
J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24.
8
Detecting an overall survival benefit that is derived from progression-free survival.检测从无进展生存中获得的总生存获益。
J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9. doi: 10.1093/jnci/djp369. Epub 2009 Nov 9.
9
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.每周一次密集剂量紫杉醇联合每3周一次卡铂治疗晚期卵巢癌：一项3期、开放标签、随机对照试验。
Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18.
10
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.在铂类难治性或耐药性卵巢癌患者中，进行的一项关于坎磷酰胺（Telcyta，TLK286）与聚乙二醇化脂质体阿霉素或拓扑替康作为三线治疗的3期随机研究。
Eur J Cancer. 2009 Sep;45(13):2324-32. doi: 10.1016/j.ejca.2009.05.016. Epub 2009 Jun 8.